Mr. Piyush Goyal, the Commerce and Industry Minister of India has vehemently refused the allegations that Indian pharma companies reproduce medicines manufactured by Swiss companies. In his recent statement, he declared that such allegations are not true and have no grounds. He further complemented that the Indian companies admire international regulations and intellectual rights.
Mr. Goyal challenged the companies making these claims to show any proof of copying. He proudly said that Indian pharmaceutical firms follow legal processes and play an important role in providing affordable healthcare across the world.
India Respects Intellectual Property Rights
Intellectual Property Rights (IPR) are special protections given to the people or companies who invent new medicines. These rights help protect their ideas from being copied. Mr. Goyal said India fully respects IPR laws and always encourages innovation.
India is known as the “Pharmacy of the World” because it makes a large number of generic medicines at low costs. These medicines are sent to many countries, helping poor and middle-income people get proper treatment.
What Is Evergreening and Why It’s a Problem?
Mr. Goyal also talked about a problem called “evergreening”. This is a strategy used by some big pharmaceutical companies. They make very small changes in their old medicines and ask for a new patent. This way, they keep owning the rights to the same medicine for a longer time and stop others from making cheaper versions.
This practice is not good for global health because it delays the entry of affordable generic medicines into the market. Mr. Goyal said evergreening hurts access to medicine, especially for countries that cannot afford high-cost treatments.
India as a Global Pharma Manufacturing Hub
India is not just producing medicines for its own people. It is also becoming a major pharma contract manufacturing company for the world. Many international pharma brands are now getting their medicines made in India due to its high-quality production, skilled workforce, and cost-effective pricing.
If you’re looking for a trusted pharma contract manufacturing company, India has many reliable firms offering full services from development to packaging.
Growth of Monopoly-Based Pharma Franchises in India
India’s pharmaceutical sector is also creating opportunities for small businesses and entrepreneurs. One such model is the monopoly pharma franchise. In this setup, a company gives a person or business exclusive rights to sell their medicines in a specific area. There is no competition from other sellers of the same brand.
This makes it easier for franchise owners to grow their business without fear of competition. Many are now starting their journey with a monopoly medicine company in India to get exclusive distribution rights and promotional support.
Conclusion
Minister Piyush Goyal’s recent statement is a strong reply to false claims made against India’s pharmaceutical industry. It shows that India is proud of its companies, their honesty, and their role in making healthcare more accessible.
By calling out evergreening and standing up for fair practices, India is also showing that it supports innovation and affordable healthcare at the same time.
With the rise of contract manufacturing and monopoly pharma franchise models, India is not just keeping up with the global pharma industry—it is leading the way forward.